The goal of this program is to improve population health by assisting clinicians and their patients to address the challenges of individualizing breast cancer treatment for women with favorable prognosis. Project 1 is concerned with the management of locoregional therapy;Project 2 with the management of systemic therapy;and Project 3 aims to evaluate a Patient Intervention decision tool. Common elements across projects include being informed by an overall conceptual model, presenting similar constructs, and sharing a methodology requiring the use of patient surveys, and the merging of -Surveillance, Epidemiology and End Results (SEER) Registry clinical data elements with information obtained from patient surveys. Finally, Projects 1 and 2 propose surveying attending clinicians of patient participants. Core B will support these cross-project activities by: overseeing the development and use of consistent survey measures, maximizing the efficiency of a uniform strategy for SEER-based sampling and rapid case ascertainment;coordinating patient and clinician survey data collection protocols;and, developing standardized methods for merging datasets. This Core will have an opportunity to advance innovative population-based methods regarding measurement reliability, validity, and durability.
The specific aims of Core B are as follows:
Aim 1 : Develop a bank of survey measures and items that will provide consistency in the measurement of common constructs across studies.
Aim 2 : Develop and implement a uniform strategy for SEER-based sampling, rapid case ascertainment, and the integration of clinical data collected through routine surveillance activities.
Aim 3 : Coordinate the development and implementation of patient and clinician surveys to maximize participant rates, minimize the number of unique patients required across studies, and minimize the administrative burden on SEER sites.
Aim 4 : Validate key clinical information collected by SEER under the new SEER 2010 data requirements against patient self-report (e.g., receipt of radiation) and other objective measures (e.g., 21 gene assay).
Aim 5 : Further inform our measurement of
Results from this program will improve public health by addressing the challenges of individualizing care for women with breast cancer. This Core will focus on advancing innovative methods in population-based cancer research by sun/eying large numbers of patients and their clinicians across three distinct areas of the United States and assessing the validity of clinical measures important in cancer quality of care research
|Wallner, Lauren P; Li, Yun; McLeod, M Chandler et al. (2017) Decision-support networks of women newly diagnosed with breast cancer. Cancer 123:3895-3903|
|Taylor, Carolyn; Correa, Candace; Duane, Frances K et al. (2017) Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol 35:1641-1649|
|Katz, Steven J; Wallner, Lauren P; Abrahamse, Paul H et al. (2017) Treatment experiences of Latinas after diagnosis of breast cancer. Cancer 123:3022-3030|
|Li, Yun; Kurian, Allison W; Bondarenko, Irina et al. (2017) The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients. Breast Cancer Res Treat 161:587-595|
|Hawley, Sarah T; Morris, Arden M (2017) Cultural challenges to engaging patients in shared decision making. Patient Educ Couns 100:18-24|
|Kurian, Allison W; Griffith, Kent A; Hamilton, Ann S et al. (2017) Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer . JAMA 317:531-534|
|Katz, Steven J; Hawley, Sarah T; Bondarenko, Irina et al. (2017) Oncologists' influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer? Breast Cancer Res Treat 165:751-756|
|Hawley, Sarah T; Janz, Nancy K; Griffith, Kent A et al. (2017) Recurrence risk perception and quality of life following treatment of breast cancer. Breast Cancer Res Treat 161:557-565|
|Jagsi, Reshma; Hawley, Sarah T; Griffith, Kent A et al. (2017) Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer. JAMA Surg 152:274-282|
|Katz, Steven J; Janz, Nancy K; Abrahamse, Paul et al. (2017) Patient Reactions to Surgeon Recommendations About Contralateral Prophylactic Mastectomy for Treatment of Breast Cancer. JAMA Surg 152:658-664|
Showing the most recent 10 out of 32 publications